No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion Total 2026 cash-based operating expenses, excluding COGS, lowered to $248 million, reflecting lower second- half spending and continued investment discipline Company reaffirms neffy base business supports a path to cash-flow breakeven in 2027 Phase 2b chronic spontaneous urticaria (CSU) program interim data read ...